Lavipharm SA, responding to the question raised by the Capital Market Commission regarding the effect of the regulatory approval to market its fentanyl transdermal system in Germany on the financial projections of the Group, as announced by the Company on 30.11.2007, clarifies that the forecasted financial figures of 2007 will not be influenced, as the launch of the product in Germany is expected to take place in the second half of 2008, as already stated in the Company's announcement on December 10th 2007, while those of 2008-2010 will be subsequently reviewed according to developments in the USA and progress in pending approvals to market the product in the remaining markets of Europe.